Login to Your Account

ArGen-X Brings in $37M for Conventional Camelid Antibodies

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 7, 2011
ArGen-X BV raised €27.5 million (US$37.1 million) in a Series B round to move its first two programs into clinical development.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription